Edition:
United States

Repros Therapeutics Inc (RPRX.OQ)

RPRX.OQ on NASDAQ Stock Exchange Capital Market

0.30USD
4:00pm EDT
Change (% chg)

$-0.00 (-1.59%)
Prev Close
$0.30
Open
$0.30
Day's High
$0.31
Day's Low
$0.29
Volume
22,905
Avg. Vol
106,216
52-wk High
$2.28
52-wk Low
$0.26

Chart for

About

Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally... (more)

Overall

Beta: 0.37
Market Cap(Mil.): $11.33
Shares Outstanding(Mil.): 37.62
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 81.40 16.08
EPS (TTM): -- -- --
ROI: -- 3.18 14.60
ROE: -- 4.93 14.03

BRIEF-Rosalind Advisors reports 5.7 pct stake in Repros Therapeutics

* Rosalind Advisors Inc reports 5.7 percent passive stake in Repros Therapeutics Inc as of July 20 - SEC filing Source text: (http://bit.ly/2gXOAhU) Further company coverage:

Jul 24 2017

BRIEF-Repros Therapeutics ‍expects to receive European patent ‍​

* Repros Therapeutics Inc - ‍expects to receive European patent that relates to selective progesterone modulators​

Jul 17 2017

BRIEF-Repros Therapeutics Q1 loss per share $0.22

* Repros Therapeutics Inc. reports first quarter 2017 financial results

May 09 2017

BRIEF-Repros Therapeutics meets with FDA to discuss Proellex in treatment of uterine fibroids

* Company holds meeting with FDA to discuss oral Proellex® in the treatment of uterine fibroids

Apr 10 2017

BRIEF-Repros names Larry Dillaha M.D. its permanent president and CEO

* Repros names Larry Dillaha, M.D., its permanent president and ceo

Apr 10 2017

BRIEF-Repros Therapeutics Inc reports • Q4 loss per share $0.16

* Repros Therapeutics Inc reports fourth quarter and year end 2016 financial results

Mar 31 2017

Earnings vs. Estimates